Clinical Trial Update: Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating efficacy and long-term safety of LUM001 (maralixibat) in progressive familial intrahepatic cholestasis has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Familial Intrahepatic Cholestasis

Drugs mentioned

• LUM001

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 2 | Status: COMPLETED | Results posted: 2021-07-12